查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607192

多形性胶质母细胞瘤治疗市场：按类型、最终用户划分 - 全球预测 2025-2030

Glioblastoma Multiforme Treatment Market by Type (Chemotherapy, Combined Modality Therapy, Medications), End-Users (Hospitals, Speciality Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年多形性胶质母细胞瘤治疗市值为31.1亿美元，预计到2024年将达到33.6亿美元，复合年增长率为8.17%，到2030年将达到53.9亿美元，预计将达到1000万美元。

多形性胶质母细胞瘤 (GBM) 是一种侵袭性脑肿瘤，需要先进的治疗策略。 GBM 治疗市场由对标靶药物、免疫疗法和精准医学等创新疗法的需求决定。鑑于 GBM 相关的高死亡率和復发率，这些治疗至关重要，需要持续的研究和开发。目前的治疗应用范围从医院环境到专门的癌症治疗中心。最终用途范围包括医疗保健提供者、患者和研究机构，重点是提高 GBM 患者的生存率和生活品质。成长要素包括生物技术的进步、肿瘤学研究投资的增加、新型药物输送系统的开发。机会比比皆是，包括加强製药公司和研究机构之间的合作、探索个人化治疗方法的遗传和分子分析以及扩大临床试验。但仍有治疗费用高、认知度低、早期检测手段不足等挑战。此外，严格的法律规范可能会延迟新疗法的核准和市场进入。具有技术创新潜力的治疗领域包括开发多标靶治疗、增强血脑障壁穿透技术以及利用人工智慧对治疗结果进行预测建模。对肿瘤微环境交互作用和神经肿瘤生物标记等领域的研究可能会产生重要的见解。 GBM 治疗市场的本质是高度竞争和动态的，其特点是技术快速进步和迫切需要有效的解决方案。企业应注重策略伙伴关係关係，参与跨学科研究，并保持灵活性以适应新的科学发现。总的来说，我们相信我们对个人化医疗、广泛的临床试验和强大的资料分析的关注将有助于推动业务成长并提高治疗效果。

主要市场统计
基准年[2023] 31.1亿美元
预测年份 [2024] 33.6亿美元
预测年份 [2030] 53.9亿美元
复合年增长率（%） 8.17%

市场动态：快速发展的多形性胶质母细胞瘤治疗市场的关键市场洞察

供需的动态交互作用正在改变多形性胶质母细胞瘤治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 脑部和神经系统疾病盛行率上升
    • 提高对脑​​部疾病和肿瘤的早期发现和治疗的认识
    • 改善各国的医疗基础设施
  • 市场限制因素
    • 多形性胶质母细胞瘤治疗相关的高成本和併发症
  • 市场机会
    • 加大投入加速临床研究
    • 治疗多形性胶质母细胞瘤新技术的出现
  • 市场挑战
    • 与多形性胶质母细胞瘤治疗相关的报销问题和严格的监管合规性

波特五力：驾驭多形性胶质母细胞瘤治疗市场的策略工具

波特的五力框架是了解多形性胶质母细胞瘤治疗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解多形性胶质母细胞瘤治疗市场的外部影响

外部宏观环境因素在塑造多形性胶质母细胞瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解多形性胶质母细胞瘤治疗市场的竞争格局

对多形性胶质母细胞瘤治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多形性胶质母细胞瘤治疗市场供应商的绩效评估

FPNV 定位矩阵是评估多形性胶质母细胞瘤治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製多形性胶质母细胞瘤治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，多形性胶质母细胞瘤治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 大脑和神经系统疾病的盛行率增加
      • 提高对脑​​部疾病和肿瘤的早期发现和治疗的认识
      • 改善整个经济领域的医疗基础设施
    • 抑制因素
      • 治疗多形性胶质母细胞瘤的高费用和併发症
    • 机会
      • 加大投入加速临床研究
      • 治疗多形性胶质母细胞瘤新技术的出现
    • 任务
      • 与多形性胶质母细胞瘤治疗相关的报销问题和严格的监管合规性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章多形性胶质母细胞瘤治疗市场：依类型

  • 化疗
  • 综合治疗
  • 药品
  • 放射治疗
  • 外科手术
  • 标靶治疗

第七章 多形性胶质母细胞瘤治疗市场：依最终用户

  • 医院
  • 专业中心

第八章美洲多形性胶质母细胞瘤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太多形性胶质母细胞瘤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲多形性胶质母细胞瘤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AIVITA Biomedical, Inc.
  • Angiochem Inc.
  • Avant Immunotherapeutics, Inc.
  • Bayer AG
  • Chimerix Inc.
  • Daiichi Sankyo Company, Limited
  • Diffusion Pharmaceuticals Inc.
  • DNAtrix, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Lineage Cell Therapeutics, Inc.
  • Merck & Co. Inc.
  • Moleculin Biotech, Inc.
  • Novocure GmbH
  • OncoSynergy, Inc.
  • Pfizer Inc.
  • Sapience Therapeutics, Inc.
  • SonALAsense
  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VBI Vaccines Inc.
  • VBL Therapeutics
Product Code: MRR-C002B1C996F6

The Glioblastoma Multiforme Treatment Market was valued at USD 3.11 billion in 2023, expected to reach USD 3.36 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 5.39 billion by 2030.

Glioblastoma Multiforme (GBM) is an aggressive form of brain cancer requiring advanced treatment strategies. The market for GBM treatments is defined by the demand for innovative therapies, such as targeted drugs, immunotherapies, and precision medicine. These treatments are crucial, given the high mortality and recurrence rates associated with GBM, necessitating ongoing research and development. Current applications extend from hospital settings to specialized cancer treatment centers. The end-use scope includes healthcare providers, patients, and research institutions focusing on improved survival rates and quality of life for GBM patients. Influencing growth factors include advancements in biotechnology, increasing investment in oncology research, and the development of novel drug delivery systems. Opportunities abound with rising collaborations between pharmaceutical companies and research institutions, the exploration of genetic and molecular profiling for personalized treatment approaches, and the expansion of clinical trials. However, the market faces challenges such as the high cost of treatment, limited awareness, and insufficient early detection methodologies. Additionally, stringent regulatory frameworks can delay approval and market entry for new treatments. Potential areas of innovation include the development of multi-targeted therapies, enhancing blood-brain barrier penetration techniques, and utilizing AI for predictive modeling in treatment outcomes. Research in areas such as tumor microenvironment interactions and neuro-oncology biomarkers could unlock significant insights. The nature of the GBM treatment market is highly competitive and dynamic, characterized by rapid technological advancements and the urgent need for effective solutions. Companies should focus on strategic partnerships, engaging in interdisciplinary research, and maintaining flexibility to adapt to new scientific findings. Overall, a focus on personalized medicine, expansive clinical trials, and robust data analytics could propel business growth and improve treatment efficacy.

KEY MARKET STATISTICS
Base Year [2023] USD 3.11 billion
Estimated Year [2024] USD 3.36 billion
Forecast Year [2030] USD 5.39 billion
CAGR (%) 8.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glioblastoma Multiforme Treatment Market

The Glioblastoma Multiforme Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of brain and neurological diseases
    • Growing awareness of early detection and treatments related to brain disorders and tumors
    • Improved healthcare infrastructure across economies
  • Market Restraints
    • High cost and complications associated with glioblastoma multiforme treatments
  • Market Opportunities
    • Increasing investments to foster clinical research
    • Emerging new techniques to treat glioblastoma multiforme
  • Market Challenges
    • Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment

Porter's Five Forces: A Strategic Tool for Navigating the Glioblastoma Multiforme Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glioblastoma Multiforme Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glioblastoma Multiforme Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glioblastoma Multiforme Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glioblastoma Multiforme Treatment Market

A detailed market share analysis in the Glioblastoma Multiforme Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glioblastoma Multiforme Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glioblastoma Multiforme Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glioblastoma Multiforme Treatment Market

A strategic analysis of the Glioblastoma Multiforme Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glioblastoma Multiforme Treatment Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical, Inc., Angiochem Inc., Avant Immunotherapeutics, Inc., Bayer AG, Chimerix Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., DNAtrix, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc., Kazia Therapeutics Limited, Lineage Cell Therapeutics, Inc., Merck & Co. Inc., Moleculin Biotech, Inc., Novocure GmbH, OncoSynergy, Inc., Pfizer Inc., Sapience Therapeutics, Inc., SonALAsense, Sumitomo Dainippon Pharma Oncology, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., VBI Vaccines Inc., and VBL Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Glioblastoma Multiforme Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chemotherapy, Combined Modality Therapy, Medications, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on End-Users, market is studied across Hospitals and Speciality Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of brain and neurological diseases
      • 5.1.1.2. Growing awareness of early detection and treatments related to brain disorders and tumors
      • 5.1.1.3. Improved healthcare infrastructure across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complications associated with glioblastoma multiforme treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments to foster clinical research
      • 5.1.3.2. Emerging new techniques to treat glioblastoma multiforme
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glioblastoma Multiforme Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combined Modality Therapy
  • 6.4. Medications
  • 6.5. Radiation Therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Glioblastoma Multiforme Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Speciality Centers

8. Americas Glioblastoma Multiforme Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Glioblastoma Multiforme Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AIVITA Biomedical, Inc.
  • 2. Angiochem Inc.
  • 3. Avant Immunotherapeutics, Inc.
  • 4. Bayer AG
  • 5. Chimerix Inc.
  • 6. Daiichi Sankyo Company, Limited
  • 7. Diffusion Pharmaceuticals Inc.
  • 8. DNAtrix, Inc.
  • 9. Eisai Co., Ltd.
  • 10. F. Hoffmann-La Roche Ltd
  • 11. Karyopharm Therapeutics Inc.
  • 12. Kazia Therapeutics Limited
  • 13. Lineage Cell Therapeutics, Inc.
  • 14. Merck & Co. Inc.
  • 15. Moleculin Biotech, Inc.
  • 16. Novocure GmbH
  • 17. OncoSynergy, Inc.
  • 18. Pfizer Inc.
  • 19. Sapience Therapeutics, Inc.
  • 20. SonALAsense
  • 21. Sumitomo Dainippon Pharma Oncology, Inc.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. VBI Vaccines Inc.
  • 25. VBL Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023